Will Glaxo’s big plans really benefit the poor?

GSK says it will make its medicines available to low income countries at a quarter of the usual price Copyright: IRD / Arnaud Luce

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Will Glaxo’s big plans really benefit the poor?</h1>
<h4></h4>
</div>
<br />
<br />

<div id="article-body">
<p><span>Andrew Witty, chief executive of GlaxoSmithKline (GSK), raised eyebrows last month by announcing that GSK will make its medicines available to low income countries at a quarter of the usual price and invest 20 per cent of its developing country profits back into local healthcare infrastructure (see <a href="http://web.scidev.net/en/news/glaxo-patent-rethink-sparks-debate.html">Glaxo patent rethink sparks debate</a></span>).</p>
<p><span>But does this reflect a real drive to improve health for people in developing countries, asks an editorial in <em>The Lancet</em>. </span></p>
<p><span>Someone will still have to pay for the cheaper medicines — and GSK prices are unlikely to match generic drug prices, says the editorial. And while 20 per cent of developing country profits sounds high, it represents less than 0.1 per cent of GSK’s overall profits.</span></p>
<p><span>More interesting is Witty’s idea of a patent pool to boost research into neglected diseases. But how it will be planned, pursued or even paid for remains to be seen, says the editorial. And GSK is not planning to share its HIV patents — despite the need for new paediatric and combination antiretroviral drugs. </span></p>
<p><span>The editorial calls for broader action and close scrutiny of efforts. Meanwhile, as an immediate test of GSK’s resolve, Witty could make GSK’s licensed human papillomavirus vaccine affordable and deliverable.</span></p>
<p><span><a target="_blank" href="http://www.thelancet.com/journals/lancet/article/PIIS0140673609604104/fulltext?rss=yes" rel="noopener noreferrer">Link to full article in <em>The Lancet</em></a>*</span></p>
<p><span>*Free registration is required to view this article</span></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/global/opinions/will-glaxo-s-big-plans-really-benefit-the-poor/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/global/opinions/will-glaxo-s-big-plans-really-benefit-the-poor/",null,true])
</script>
</div>

Andrew Witty, chief executive of GlaxoSmithKline (GSK), raised eyebrows last month by announcing that GSK will make its medicines available to low income countries at a quarter of the usual price and invest 20 per cent of its developing country profits back into local healthcare infrastructure (see Glaxo patent rethink sparks debate).

But does this reflect a real drive to improve health for people in developing countries, asks an editorial in The Lancet.

Someone will still have to pay for the cheaper medicines — and GSK prices are unlikely to match generic drug prices, says the editorial. And while 20 per cent of developing country profits sounds high, it represents less than 0.1 per cent of GSK’s overall profits.

More interesting is Witty’s idea of a patent pool to boost research into neglected diseases. But how it will be planned, pursued or even paid for remains to be seen, says the editorial. And GSK is not planning to share its HIV patents — despite the need for new paediatric and combination antiretroviral drugs.

The editorial calls for broader action and close scrutiny of efforts. Meanwhile, as an immediate test of GSK’s resolve, Witty could make GSK’s licensed human papillomavirus vaccine affordable and deliverable.

Link to full article in The Lancet*

*Free registration is required to view this article